Data fragmentation and inefficiency are most evident in the quality reporting approach currently used for accountable care ...

We aim to provide transparency in how Elevance Health plans address variations in clinical practices to ensure safe, ...

Margolis Center for Health Policy to the pod to discuss her recent Forefront article focused on how ACO REACH enabled ACOs to ...

Taylor holds a bachelor’s degree from the University of Washington (UW) School of Engineering in technical communication and a master’s degree in clinical informatics and patient-centered technology ...

Geoffrey Crawford serves as Staff Vice President of Medical Policy (US) for The Elevance Health Companies, Inc.

The majority of promotional expenditures are invested in drug samples, one of the industry’s most important marketing tactics ...

When the sole manufacturer withdrew a critical cancer drug from Medicare and Medicaid, patients were left without options.

In late August 2025, CMS released Performance Year (PY) 2024 data for the Medicare Shared Savings Program (MSSP). This marked ...

The 340B rebate pilot model set to begin in January 2026 starkly presents the key tradeoff between program integrity and ...

A 2026 CMS proposed rule contains multiple provisions that will improve the transparency of hospital prices and support the ...

The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...

The No UPCODE Act—with some refinements—is a good start insofar it establishes some key pieces of reform, but a broader ...